Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Biotechnology

Healthcare
$1.43 -2.40%

-$0.04 today

Market cap
$82.18M
Beta
3.23
P/E (TTM)
-2.2
EPS (TTM)
-$0.75
52W Low $1.62High $4.94

Volume 0.60M

Average 1.31M

BDTX Short-term Investments

Marketable securities and deposits the company expects to convert to cash within a year.

Black Diamond Therapeutics, Inc.NASDAQ: BDTX

Short-term Investments · Q1 FY2026 · quarter ended Mar 2026

Short-term investments rises 63.4% from a year ago

Short-term investments stood at $88.19M at the end of Q1 FY2026, up 63.4% from a year earlier and down 18.1% from the prior quarter. Over 3 fiscal years it compounded at +6.8% a year.

Context

  • Short-term investments amounted to 66.3% of total assets at the end of Q1 FY2026, up 35.7 pp from a year earlier.
  • Short-term investments increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether short-term investments keeps rising in the next quarterly balance sheet after a +63.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$88.19M-18.1% QoQ
Last fiscal yearDec 2025
$107.66M+73.3% YoY
Year agoMar 2025
$53.98M+63.4% since
Short-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+63.4%——
1 year+73.3%——
3-year CAGR+6.8%——
5-year CAGR——
10-year CAGR——

Short-term Investments history

USD · from the balance sheet

Latest · FY2025
107.66M USD
Year-over-year change
+73.3%
4-year CAGR
-7.0%

Short-term Investments vs competitors

How BDTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +63.4% is the highest of 7, against a peer median of -40.4%.
  • Short-term investments amounts to 66.3% of total assets for BDTX, versus a peer median of 35.1%.
BDTX Competitors
Short-term Investments for BDTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$128.85M USD-3.2%-8.6%40.9%
IMRXImmuneering CorporationMar 2026$109.37M USD—+10.3%0.1%
ABEOAbeona Therapeutics Inc.Mar 2026$106.9M USD+56.7%+43.9%53.9%
CRBUCaribou Biosciences, Inc.Mar 2026$105.57M USD-41.0%-12.5%70.9%
FHTXFoghorn Therapeutics Inc.Mar 2026$95.97M USD-39.9%-35.7%43.2%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$88.19M USD+63.4%+6.8%66.3%
AVTXAvalo Therapeutics, Inc.Mar 2026$57.01M USD——57.1%
AARDAardvark Therapeutics, Inc. Common StockMar 2026$28.76M USD-76.9%+386.8%29.2%
FENCFennec Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
IVAInventiva S.A.Dec 2025€0 EUR——0.0%
TNYATenaya Therapeutics, Inc.Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding BDTX) —-40.4%+0.9%35.1%

Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents65.8M34.32M56.22M36.44M20.99M
Short-term Investments143.99M88.49M75.18M62.14M107.66M
Net Receivables00000
Inventory00000
Other Current Assets04.9M2.63M2.6M3.79M
Total Current Assets215.7M127.71M134.03M101.18M132.44M
Property, Plant & Equipment (Net)30.74M27.38M23.71M20.4M9.67M
Goodwill00000
Intangible Assets00000
Long-term Investments0000829K
Tax Assets00000
Other Non-current Assets1.24M1.17M823K1.07M73K
Total Non-current Assets31.98M28.55M24.53M21.46M10.57M
Total Assets247.68M156.26M158.57M122.64M143.01M
Account Payables4.11M1.88M2.32M4.01M579K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities23.64M15.26M19.65M20.57M15.73M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities28.14M25.3M22.19M18.78M15.07M
Total Liabilities51.78M40.56M41.83M39.36M30.8M
Common Stock5K5K7K7K8K
Retained Earnings(243.82M)(334.99M)(417.43M)(487.11M)(464.74M)
Accumulated OCI(414K)(1.82M)(27K)24K101K
Other Stockholders Equity00000
Minority Interest00000
Total Equity195.9M115.7M116.74M83.29M112.21M
Total Debt28.46M28.14M25.3M22.19M18.78M
Net Debt(37.34M)(6.18M)(30.92M)(14.25M)(2.21M)

Black Diamond Therapeutics, Inc.

NASDAQ:BDTX

Intrinsic Alpha fair value

Locked

Current Price

$1.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.